Literature DB >> 23846417

Considerations for the prediction of survival time in pancreatic cancer based on registry data.

Gaurav Bajaj1, Erin Dombrowsky, Qilu Yu, Banke Agarwal, Jeffrey S Barrett.   

Abstract

Semi-parametric and parametric survival models in patients with pancreatic adenocarcinoma (PC) using data from Surveillance, Epidemiology, and End Result (SEER) registry were developed to identify relevant covariates affecting survival, verify against external patient data and predict disease outcome. Data from 82,251 patients was extracted using site and histology codes for PC in the SEER database and refined based on specific cause of death. Predictors affecting survival were selected from SEER database; the analysis dataset included 2,437 patients. Survival models were developed using both semi-parametric and parametric approaches, evaluated using Cox-Snell and deviance residuals, and predictions were assessed using an external dataset from Saint Louis University (SLU). Prediction error curves (PECs) were used to evaluate prediction performance of these models compared to Kaplan-Meier response. Median overall survival time of patients from SEER data was 5 months. Our analysis shows that the PC data from SEER was best fitted by both semi-parametric and the parametric model with log-logistic distribution. Predictors that influence survival included disease stage, grade, histology, tumor size, radiation, chemotherapy, surgery, and lymph node status. Survival time predictions from the SLU dataset were comparable and PECs show that both semi-parametric and parametric models exhibit similar predictive performance. PC survival models constructed from registry data can provide a means to classify patients into risk-based subgroups, to predict disease outcome and aide in the design of future prospective randomized trials. These models can evolve to incorporate predictive biomarker and pharmacogenetic correlates once adequate causal data is established.

Entities:  

Mesh:

Year:  2013        PMID: 23846417     DOI: 10.1007/s10928-013-9327-z

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  18 in total

1.  Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag?

Authors:  Stephen A Welch; Malcolm J Moore
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

2.  Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development.

Authors:  Y Wang; C Sung; C Dartois; R Ramchandani; B P Booth; E Rock; J Gobburu
Journal:  Clin Pharmacol Ther       Date:  2009-05-13       Impact factor: 6.875

3.  Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

Authors:  Laurent Claret; Pascal Girard; Paulo M Hoff; Eric Van Cutsem; Klaas P Zuideveld; Karin Jorga; Jan Fagerberg; René Bruno
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

Review 4.  Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).

Authors:  Mariacristina Di Marco; Roberto Di Cicilia; Marina Macchini; Elisabetta Nobili; Silvia Vecchiarelli; Giovanni Brandi; Guido Biasco
Journal:  Oncol Rep       Date:  2010-05       Impact factor: 3.906

5.  Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.

Authors:  Andrew H Ko; Anne M Espinoza; Kimberly A Jones; Alan P Venook; Emily K Bergsland; Robin K Kelley; Elizabeth Dito; Anna Ong; Cherry S Hanover; Fergus V Coakley; Margaret A Tempero
Journal:  Am J Clin Oncol       Date:  2012-10       Impact factor: 2.339

6.  Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

Authors:  Margaret A Tempero; J Pablo Arnoletti; Stephen W Behrman; Edgar Ben-Josef; Al B Benson; Ephraim S Casper; Steven J Cohen; Brian Czito; Joshua D I Ellenhorn; William G Hawkins; Joseph Herman; John P Hoffman; Andrew Ko; Srinadh Komanduri; Albert Koong; Wen Wee Ma; Mokenge P Malafa; Nipun B Merchant; Sean J Mulvihill; Peter Muscarella; Eric K Nakakura; Jorge Obando; Martha B Pitman; Aaron R Sasson; Anitra Tally; Sarah P Thayer; Samuel Whiting; Robert A Wolff; Brian M Wolpin; Deborah A Freedman-Cass; Dorothy A Shead
Journal:  J Natl Compr Canc Netw       Date:  2012-06-01       Impact factor: 11.908

7.  Assessing the performance of prediction models: a framework for traditional and novel measures.

Authors:  Ewout W Steyerberg; Andrew J Vickers; Nancy R Cook; Thomas Gerds; Mithat Gonen; Nancy Obuchowski; Michael J Pencina; Michael W Kattan
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

8.  How to assess prognostic models for survival data: a case study in oncology.

Authors:  M Schumacher; E Graf; T Gerds
Journal:  Methods Inf Med       Date:  2003       Impact factor: 2.176

9.  On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studies.

Authors:  R Bruno; L Claret
Journal:  Clin Pharmacol Ther       Date:  2009-08       Impact factor: 6.875

10.  A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?

Authors:  Andrew H Ko; Elizabeth Dito; Brian Schillinger; Alan P Venook; Zhidong Xu; Emily K Bergsland; Derrick Wong; Janet Scott; Jimmy Hwang; Margaret A Tempero
Journal:  Invest New Drugs       Date:  2008-04-01       Impact factor: 3.850

View more
  1 in total

1.  Application of a hazard-based visual predictive check to evaluate parametric hazard models.

Authors:  Yeamin Huh; Matthew M Hutmacher
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-13       Impact factor: 2.745

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.